Inloggad som:
MK-3543-007
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
MK-3543-007
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
A Phase 3, Randomized, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) versus Hydroxyurea in Participants with Previously-Untreated Essential Thrombocythemia
PLACEHOLDER
A Phase 3, Randomized, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) versus Hydroxyurea in Participants with Previously-Untreated Essential Thrombocythemia
Mer information om studien för vårdgivare
Has a diagnosis of ET per WHO diagnostic criteria for myeloproliferative neoplasmsHas a bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis (Appendix 11) / Has received no prior cytoreductive treatment for their ET
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to bomedemstat or LSDi (ie, monoamine oxidase inhibitors; MAOIs) that contraindicates participation /History of any illness/impairment of gastrointestinal (GI) function that might interfere with drug abs
Behandling
Fas 3
Prevention
Företag
Studien ändrades senast av: studysonia (2024-12-05)